Education
About Us
Working with TipRanks
Follow Us
Irhythm Technologies (IRTC)
NASDAQ:IRTC
Top Page
Irhythm Technologies
(NASDAQ:IRTC)
Select Model
Select Model
Rating:54Neutral
Price Target:
$154.00
▲(19.88% Upside)
Action:ReiteratedDate:02/23/26
The score is driven primarily by improving fundamentals and a positive outlook from the latest earnings call (growth, margin expansion, and rising free cash flow). Offsetting this are elevated balance-sheet leverage, still-negative profitability/negative P/E, and weak technicals with the stock trading below key moving averages.
Positive Factors
Market leadership in long‑term monitoring
iRhythm’s dominant ~72% share in long‑term continuous monitoring and extensive clinical literature create durable competitive advantages. High share yields scale economics, entrenched clinical credibility and referral patterns that support sustained volume growth and pricing power in a segment growing in the high teens.
Improving margins and cash generation
Material margin expansion (70%+ gross margin) plus a clear swing to positive operating and free cash flow meaningfully reduces funding pressure. Reliable cash generation supports reinvestment in commercialization, product development and debt paydown, improving durability of the business model over coming quarters.
Large data, AI pilots and EHR traction
A massive curated ECG dataset and extensive EHR integration create structural advantages for algorithmic improvement, clinical validation and stickiness. Primary care adoption and AI pilots increase addressable market and channel diversification, supporting sustained unit growth and defensible differentiation.
Negative Factors
High leverage and thin equity
A markedly more levered capital structure limits financial flexibility: high absolute debt and thin equity increase refinancing, covenant and interest‑rate risks. Elevated leverage constrains strategic optionality, heightens vulnerability to revenue shocks and can sap investment capacity over the medium term.
Still loss‑making on full‑year basis
Although margins and EBITDA improved, the company remained loss‑making for FY2025. Persistent net losses prevent internal capitalization of growth indefinitely, maintain pressure on equity returns, and mean earnings durability depends on continued execution to convert margin gains into sustained GAAP profitability.
Regulatory and product‑timing uncertainty
A DOJ inquiry into Zio AT reimbursement claims plus an FDA‑driven delay to next‑gen MCT create structural execution and reimbursement risk. These issues can alter payer dynamics, require remediation spend, and postpone anticipated product‑led revenue, adding lasting uncertainty to growth and margin plans.
Irhythm Technologies (IRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.15B
Dividend YieldN/A
Average Volume (3M)638.76K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth25.45%
EPS Growth66.62%
CountryUS
Employees2,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.17
Shares Outstanding32,316,760
10 Day Avg. Volume699,215
30 Day Avg. Volume638,759
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.14
Enterprise Value/Gross Profit8.69
Enterprise Value/Ebitda-582.52
Forecast
1Y Price Target
$213.00Price Target Upside65.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$874.98M
Irhythm Technologies Business Overview & Revenue Model
Company DescriptioniRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
How the Company Makes MoneyiRhythm Technologies generates revenue primarily through the sale of its Zio service, which includes both device rentals and associated diagnostic services. The company charges healthcare providers for the use of its monitoring devices and the analysis of the collected data. Key revenue streams include reimbursements from insurance companies and government programs for the services rendered. Additionally, iRhythm has established strategic partnerships with healthcare organizations and technology providers to expand its market reach and enhance its service offerings, contributing to its overall earnings.
Irhythm Technologies Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Q4 2025 revenue of $208.9M, up 27.1% year-over-year; FY2025 revenue of $747.1M, up 26.2% YoY. Fifth consecutive quarter with revenue growth above 20%.
Profitability and Cash Flow Milestones
First positive quarterly net income in company history: Q4 net income $5.6M ($0.17 dil. EPS). Full-year adjusted EBITDA $68.9M (9.2% of revenue) with Q4 adjusted EBITDA $34.3M (16.4% of revenue, +470 bps YoY). Free cash flow of $14.5M in Q4 and $34.5M for FY2025; ended year with $583.8M in cash, cash equivalents and marketable securities.
Margin Expansion
Gross margin improved to 70.9% in Q4 (up 90 bps YoY) and 70.6% for the full year (up 170 bps YoY). Significant adjusted EBITDA margin expansion (Q4 16.4%; FY improvement >1,000 bps YoY).
Market Leadership in Long‑Term Continuous Monitoring
Estimated ~72% share in long-term continuous monitoring (segment growing in the high teens). Supported by clinical credibility: more than 135 scientific publications.
Zio AT Momentum and MCT Platform Positioning
Zio AT unit growth ran more than twice the company average for the year and management stated AT grew north of 50% YoY; MCT market share approximately 15%. Next‑generation MCT (21‑day wear, improved form factor and algorithms) under FDA review with expected commercial release in H1 2027.
Commercial Expansion and EHR Integration
More than one‑third of volume originated in primary care; company serves ~40,000 primary care physicians. Over 50% of volume flows through EHR‑integrated accounts; 75 of top 100 customers fully integrated. Home enrollment ~23% of U.S. volume.
Data and AI Capabilities
Nearly 3 billion hours of curated ECG data and ~13M patients in the database. Early predictive AI pilots (with Lucem Health) reported more than 85% accuracy in pre‑identifying patients with clinically relevant arrhythmias.
International and Adjacent Market Progress
Commercial presence in the U.K., select EU markets and Japan; U.K. delivered the largest quarter of volume to date. Active sleep pilots targeting the ~40M U.S. sleep apnea patients; international markets collectively run ~3M ambulatory cardiac tests annually representing a large long‑term opportunity (current share <1%).
Forward Guidance and Profitability Roadmap
2026 guidance: revenue $870M–$880M (16%–18% growth), gross margin expected to improve ~80–100 bps vs 2025, and adjusted EBITDA margin expected to expand to 11.5%–12.5% for FY2026 (Q1 adj. EBITDA margin 3%–4%).
Negative Updates
Next‑Gen MCT Timing and FDA Questions
Next‑generation MCT release pushed into first half of 2027 due to FDA questions and required move to a new mobile gateway (cybersecurity and submission updates). This delay creates timing risk for anticipated MCT revenue contributions.
Full‑Year Net Loss and Rising Operating Expenses
Full‑year 2025 net loss of $44.6M (loss of $1.39 per diluted share). Operating expenses for FY2025 were $584.7M (up 11.8% YoY); Q4 operating expenses were $145.8M versus $119.2M prior year.
Regulatory and Reimbursement Uncertainty
Industry scrutiny around chart‑derived diagnoses (CMS activity) and evolving reimbursement policies create uncertainty. Management did not include any potential upside from chart‑scraping policy shifts in guidance; Medicare dynamics are mixed (Zio Monitor rates up, AT Medicare rates slightly down).
One‑Time Collections True‑Up and Pricing Conservatism
Q4 price improvement included a one‑time collections reserve true‑up (low single‑digit millions), which management did not fully assume in 2026 guidance; 2026 pricing guidance stands roughly flat to 2025 despite some Medicare rate changes.
Limited Near‑Term Contribution from Innovative and International Channels
Innovative channel remains a small portion (low single digits of revenue) with limited visibility despite exit‑rate step‑up; international markets currently represent <1% share in target countries and are early stage — meaningful contribution expected further out (2027+).
Remaining FDA Remediation and Implementation Costs
Management indicated ongoing remediation and FDA‑related work that adds costs today (though expected to moderate over time), constraining near‑term margin upside.
MCT and Gateway Technology Tradeoffs
Decision to move to a locked mobile gateway (initially provided device rather than patient smartphone) to address cybersecurity adds development and deployment complexity and may slow broader feature rollout (patient‑device smartphone integration deferred to a later iteration).
Company Guidance
iRhythm guided full-year 2026 revenue of $870–$880 million, implying 16–18% y/y growth versus 2025 revenue of $747.1 million (2025 growth 26.2%), with first‑quarter 2026 revenue of $193–$195 million; pricing is expected to be roughly flat to 2025 while gross margin should improve ~80–100 basis points versus 2025 (FY 2025 gross margin 70.6%, Q4 70.9%). 2026 adjusted EBITDA margin is expected to expand to 11.5–12.5% (Q1 ~3–4%), up from full‑year 2025 adjusted EBITDA of $68.9 million (9.2%) and Q4 adjusted EBITDA of $34.3 million (16.4%), and free cash flow is expected to grow versus 2025’s $34.5 million (Q4 FCF $14.5 million) with FCF skewed to the second half; year‑end 2025 cash, cash equivalents and marketable securities totaled $583.8 million. The company also said international should grow slightly ahead of company averages, Zio AT and innovative channels are expected to outpace core growth (though AT in 2026 is forecasted to grow ahead of the company but below the ~2x pace seen in 2025), and management remains focused on operational leverage as it pursues a $1 billion revenue target in 2027.Irhythm Technologies Financial Statement Overview
Summary
Operations are improving (2025 revenue re-acceleration, ~70%+ gross margin, and a major swing to positive operating and free cash flow), but the balance sheet is a meaningful risk with very high leverage versus thin equity and the company still posting a full-year net loss.Income Statement
Revenue growth has re-accelerated in 2025 (6.3% vs ~0.2% in 2024), and gross margin remains strong and improving (about 70.6% in 2025 vs 68.9% in 2024). However, profitability is still the key issue: the company remains loss-making (net margin about -6.0% in 2025), even though losses narrowed meaningfully versus 2024 (net margin about -19.1%). Overall, the trajectory is improving, but earnings quality is not yet proven given continued operating losses.44
Neutral
Balance Sheet
Leverage is the primary weakness. Total debt is very high relative to equity, with debt-to-equity rising sharply from ~0.62 in 2023 to ~8.11 in 2024 and ~4.79 in 2025, signaling a much more levered capital structure. Equity is relatively thin ($153M vs $731M of debt in 2025), which reduces financial flexibility. Returns on equity are negative due to ongoing losses, though improved in 2025 versus 2024.23
Negative
Cash Flow
Cash generation improved substantially in 2025: operating cash flow turned solidly positive ($81M) versus near-breakeven in 2024 ($3M), and free cash flow swung to positive ($81M) from negative in 2024 (-$31M). This is a notable strength and reduces near-term funding pressure, although the cash flow profile has been volatile historically (negative operating and free cash flow in 2020–2023).63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 747.14M | 591.84M | 492.68M | 410.92M | 322.82M |
| Gross Profit | 527.25M | 407.53M | 331.81M | 281.63M | 213.57M |
| EBITDA | -3.96M | -74.13M | -96.86M | -92.14M | -83.23M |
| Net Income | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
Balance Sheet | |||||
| Total Assets | 1.02B | 931.45M | 433.14M | 448.22M | 462.97M |
| Cash, Cash Equivalents and Short-Term Investments | 583.76M | 535.55M | 133.76M | 213.14M | 239.13M |
| Total Debt | 731.18M | 736.91M | 129.82M | 131.04M | 117.71M |
| Total Liabilities | 867.30M | 840.54M | 223.05M | 208.41M | 183.45M |
| Stockholders Equity | 152.75M | 90.91M | 210.10M | 239.81M | 279.51M |
Cash Flow | |||||
| Free Cash Flow | 34.52M | -30.55M | -90.53M | -52.84M | -65.82M |
| Operating Cash Flow | 80.86M | 3.39M | -50.10M | -23.01M | -37.75M |
| Investing Cash Flow | -277.06M | -122.98M | -1.21M | -52.43M | 105.26M |
| Financing Cash Flow | 12.61M | 511.38M | 8.82M | 26.72M | -28.58M |
Irhythm Technologies Technical Analysis
Negative
128.46
Price Trends
160.95
Negative
169.41
Negative
162.30
Negative
Market Momentum
-7.28
Positive
32.59
Neutral
12.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRTC, the sentiment is Negative. The current price of 128.46 is below the 20-day moving average (MA) of 146.84, below the 50-day MA of 160.95, and below the 200-day MA of 162.30, indicating a bearish trend. The MACD of -7.28 indicates Positive momentum. The RSI at 32.59 is Neutral, neither overbought nor oversold. The STOCH value of 12.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRTC.
Irhythm Technologies Risk Analysis
Irhythm Technologies disclosed 59 risk factors in its most recent earnings report. Irhythm Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Irhythm Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.84B | -15.70 | -19.24% | ― | 8.97% | -1024.86% | |
66 Neutral | $1.85B | 13.06 | 19.77% | ― | 16.81% | 34.90% | |
64 Neutral | $2.97B | 30.09 | 6.11% | ― | 7.81% | -26.32% | |
64 Neutral | $725.83M | 78.09 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $1.59B | -90.49 | -1.90% | ― | 18.72% | 85.77% | |
54 Neutral | $4.15B | -91.05 | -36.57% | ― | 25.45% | 66.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IRTC
Irhythm Technologies
128.46
21.17
19.73%
ITGR
Integer Holdings
86.34
-31.89
-26.97%
AXGN
AxoGen
30.65
12.03
64.61%
LIVN
LivaNova
70.27
28.71
69.08%
INSP
Inspire Medical Systems
64.81
-116.27
-64.21%
BVS
Bioventus
8.77
-1.32
-13.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.